|
Session 99
Poster Abstracts
Clinical Pharmacology of NRTIs, NNRTIs, and Integrase Inhibitors
Tuesday, 1 - 4 pm
Poster Hall |
| 557 |
Abacavir Plasma Pharmacokinetics in the Absence and the Presence of Atazanavir/Ritonavir or Lopinavir/Ritonavir) and Vice Versa in HIV+ Patients
Laura Waters*1, G Moyle1, A D’Avolio2, M Sciandra2, L Else3, A Pozniak1, M Nelson1, B Gazzard1, D Back3, and M Boffito1
1Chelsea and Westminster Hosp, London, UK; 2Univ of Turin, Italy; and 3Univ of Liverpool, UK |
| 558 |
Disease-based Model Prediction of Treatment Response to Apricitabine for Viruses with Reduced Susceptibility
P Smith1, Alan Forrest*1, Y Brun1, J Sawyer2, and S Cox3
1State Univ of New York at Buffalo, US; 2Prism Ideas, Nantwich, Cheshire, UK; and 3Avexa, Richmond, Victoria, Australia |
559
 |
Expression of Nucleoside Analog Uptake Transporters and Entry Mechanisms of AZT in Immune Cells
Gerard Minuesa*1, S Purcet2, I Erkizia1, M Molina Arcas2, F Casado2, B Clotet1, M Pastor Anglada2, J Martínez Picado1,3, and J Martínez Picado1,3
1Fndn irsiCaixa, Hosp Germans Trias i Pujol, Univ Autonoma de Barcelona, Badalona, Spain; 2Univ of Barcelona, Spain; and 3Inst Catalana de Recerca i Estudis Avançats, Barcelona, Spain |
560
|
Pharmacokinetics and Pharmacodynamics of TMC125 in HIV-infected Patients with NNRTI and PI Resistance: TMC125-C223
Thomas Kakuda*1, M Schöller-Gyüre2, M Peeters2, J Vingerhoets2, C Corbett2, B Woodfall2, and R Hoetelmans2
1Tibotec Inc, Yardley, PA, US and 2Tibotec BVBA, Mechelen, Belgium |
561
|
Pharmacokinetic Interaction between Efavirenz and Diltiazem or Itraconazole after Multiple-dose Administration in Adult Healthy Subjects
S Kaul, P Ji, J Dudley, W Wu, D Whigan, C Olszyk, P Nandy, E Hughes, and Dennis Grasela*
Bristol-Myers Squibb Pharma Res Inst, Princeton, NJ, US |
| 562 |
A Double-blind, Parallel, Randomized, Placebo-controlled, Single and Repeat Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor GSK364735 in Healthy Subjects (GRZ105655)
Sunila Reddy*1, S Min1, J Borland1, I Song1, J Lin1, A Mehta1, S Palleja2, and W Symonds1
1GlaxoSmithKline, Research Triangle Park, NC, US and 2Shionogi USA, Inc, Florham Park, NJ, US |
|
